| Schedule of Segment Information |
The following table presents selected financial information with respect to the Company’s single operating segment (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Collaboration revenue |
|
$ |
148 |
|
|
$ |
— |
|
|
$ |
148 |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
External research and development expense -
Zolucatetide |
|
|
12,673 |
|
|
|
9,379 |
|
|
|
25,767 |
|
|
|
22,524 |
|
External research and development expense -
ß-Catenin Degrader |
|
|
799 |
|
|
|
193 |
|
|
|
1,215 |
|
|
|
912 |
|
External research and development expense -
ERG |
|
|
1,970 |
|
|
|
1,842 |
|
|
|
4,882 |
|
|
|
3,482 |
|
External research and development expense -
ARON |
|
|
1,959 |
|
|
|
751 |
|
|
|
3,365 |
|
|
|
1,616 |
|
External research and development expense -
Early discovery and other programs |
|
|
1,021 |
|
|
|
1,245 |
|
|
|
2,015 |
|
|
|
2,239 |
|
Other research and development expenses |
|
|
8,319 |
|
|
|
7,462 |
|
|
|
15,969 |
|
|
|
14,034 |
|
Personnel-related research and development
expenses (excluding stock-based
compensation expense) |
|
|
11,362 |
|
|
|
8,471 |
|
|
|
21,594 |
|
|
|
17,609 |
|
Personnel-related general and administrative
expenses (excluding stock-based
compensation expense) |
|
|
2,487 |
|
|
|
2,252 |
|
|
|
5,596 |
|
|
|
4,663 |
|
Other general and administrative expenses |
|
|
6,217 |
|
|
|
3,484 |
|
|
|
11,947 |
|
|
|
6,735 |
|
Depreciation and amortization expense |
|
|
593 |
|
|
|
618 |
|
|
|
1,199 |
|
|
|
1,272 |
|
Stock-based compensation expense |
|
|
3,634 |
|
|
|
823 |
|
|
|
4,938 |
|
|
|
1,675 |
|
Other segment items(1) |
|
|
1,577 |
|
|
|
(1,710 |
) |
|
|
(560 |
) |
|
|
(3,625 |
) |
Consolidated net loss |
|
$ |
(52,463 |
) |
|
$ |
(34,810 |
) |
|
$ |
(97,779 |
) |
|
$ |
(73,136 |
) |
Notes (1)Other segment items consist of interest income, interest expense, sublease income – related party, and change in fair value of simple agreement for future equity.
|